Amicoat provides the next-generation antimicrobial technology for medical devices - by Nature
The hard reality
Healthcare-associated infections (HAIs) affect 1 in 10 patients worldwide, and with one in three related bacteria resistant to antibiotics, there is an urgent need for innovative strategies to reduce infection rates.
Our solution – by Nature
Antimicrobial peptides have been effective for 450+ million years, and inspired the development of voxvoganan by Amicoat – effective against 250+ microbes including those resistant to antibiotics.
Amicoat is a world-leader in pioneering antimicrobial peptides – by Nature
Amicoat was founded based on world-leading research at the Arctic University of Norway UiT. Our purpose is to improve medical devices and save lives by providing our patented, unique and sustainable antimicrobial coating technology.
Antimicrobial peptides (AMPs) are cornerstones of the innate immune system across species, and voxvoganan developed by Amicoat is a unique and optimal AMP that enables next-generation antimicrobial technology for medical devices.
Voxvoganan is our optimal antimicrobial peptide for medical devices
Amicoat supports our partners through the product development – from idea to market
Our scientists support partners in testing the feasibility of incorporating our antimicrobial peptide voxvoganan in relevant materials for medical devices, and our regulatory documentation provides a solid foundation for regulatory processes.
Healthcare-associated infections (HAIs) and antimicrobial resistance are growing challenges. Innovations such as voxvoganan from Amicoat enable the next-generation medical devices to minimize the rate of infections and limit healthcare costs worldwide.
Amicoat and our team utilize patented technology to solve global challenges
